Hypertrophic Cardiomyopathy (HCM)
35
12
16
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
2.9%
1 terminated out of 35 trials
80.0%
-6.6% vs benchmark
9%
3 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 4 completed trials
Clinical Trials (35)
Radiomics Analysis of CMR Imaging for Arrhythmic Risk Prediction in Hypertrophic Cardiomyopathy, With Longitudinal Risk Reassessment After Mavacamten Therapy in Obstructive Patients
Aom0304 in Adult Patients With Symptomatic Hypertrophic Cardiomyopathy
LA-HCM Study : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients With Abnormal Left Atrial Strain.
A Real-world HCM-cohort Trial
Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy
COLLIGO-HCM: A Multinational Observational Study of the Real-World Effectiveness of Mavacamten Among Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
Multicentre Hypertrophic Cardiomyopathy Registry
Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy
Perfusion Abnormalities in Hypertrophic Cardiomyopathy
HCMR Re-Imaging Study
Application of [68Ga]Ga-NI-FAPI-04 PET/CT Imaging in Fibroblast Activation Protein Related Diseases
ENABLE-HCM - AI-ENabled Echocardiography With Ultrasound Beyond the Echo Lab for Better HCM Imaging and Expanded Access
Mechanisms of Atrial Pathoelectrophysiology in HCM
Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3773274 in Adults With Hypertrophic Cardiomyopathy
Retrospective Natural History Study of RASopathy-associated Cardiomyopathy (RAS-CM)
Precision Pharmacogenetics and Genotype Class Based Prediction of Mavacamten Response in Obstructive Hypertrophic Cardiomyopathy
One-stop Evaluation of Hypertrophic Cardiomyopathy in Cardiac Magnetic Resonance
Multimodal Analysis of Endomyocardial Biopsies
The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction
The Application of T1 Mapping in Real-World